{ "schemaVersion": 2, "eyebrow": "Critical Care", "title": "Sepsis Vasopressor Selection", "summary": "Use norepinephrine early to restore a mean arterial pressure of at least 65 mm Hg after initial fluid resuscitation; add fixed-dose vasopressin during escalating requirements, reserve epinephrine for persistent hypotension, and reassess for cardiogenic or obstructive physiology when shock does not respond.", "seoDescription": "Point-of-care selection and escalation of norepinephrine, vasopressin, epinephrine, and angiotensin II for adult septic shock.", "clinicalQuestion": "Which vasopressor strategy best restores perfusion in adults with septic shock and persistent hypotension after initial resuscitation?", "specialty": "Critical Care Medicine", "audience": "U.S. physicians and medical trainees", "tags": [ "septic shock", "norepinephrine", "vasopressin", "epinephrine", "angiotensin II", "mean arterial pressure", "vasopressor escalation" ], "keyTakeaways": [ "For adults with septic shock, use norepinephrine as the first-line vasopressor rather than dopamine, vasopressin, epinephrine, or angiotensin II. [10]", "Do not wait for completion of fluid resuscitation when hypotension persists; initiate norepinephrine early and target MAP at least 65 mm Hg. [5]", "During escalating norepinephrine requirements, add vasopressin at a fixed 0.03 U/min rather than continuing catecholamine escalation alone; a norepinephrine requirement near 0.25 µg/kg/min is a commonly used trigger. [10][12]", "Avoid dopamine when alternatives are available: compared with norepinephrine, it is associated with higher mortality and substantially more arrhythmia. [20]", "Interpret persistent lactate elevation alongside capillary refill, urine output, clinical perfusion, cardiac output, and catecholamine exposure; epinephrine and endogenous adrenergic stimulation can raise lactate independently of global hypoperfusion. [4][20]" ], "sections": [ { "id": "start-norepinephrine", "eyebrow": "First-line choice", "heading": "When to start norepinephrine and what pressure target to use", "intro": "Treat persistent vasodilatory hypotension while continuing resuscitation and infection-directed therapy.", "paragraphs": [ "Start norepinephrine when MAP remains below approximately 60 to 65 mm Hg after initial fluid resuscitation, or earlier when ongoing hypotension is causing impaired perfusion. Expert consensus supports not delaying vasopressor therapy until fluids are complete; the operational initial target is MAP at least 65 mm Hg. [5][11]", "Norepinephrine is the preferred initial vasopressor in adult septic shock. The Surviving Sepsis Campaign makes a strong recommendation for norepinephrine over dopamine, vasopressin, epinephrine, selepressin, and angiotensin II as first-line therapy. Its predominantly peripheral vasoconstrictor effect with modest inotropy makes it suitable for most vasodilatory shock states. [10][2]", "Escalate therapy according to MAP and evidence of perfusion, not MAP alone. Follow mental status, urine output, skin temperature and capillary refill, serial lactate, and the trajectory of vasopressor requirement. An elevated lactate may represent impaired oxygen delivery, but adrenergic stimulation—including administered epinephrine—can increase lactate production without global hypoperfusion. [4][20]" ], "bullets": [ "Use MAP at least 65 mm Hg as the initial resuscitation target; individualize upward targets cautiously in chronic hypertension when perfusion remains inadequate at that pressure. [5]", "If norepinephrine is unavailable, epinephrine or dopamine are alternatives, but prioritize restoring access to norepinephrine; use particular caution with either alternative in patients at risk for arrhythmia. [10]", "A rising vasopressor requirement should trigger reassessment of intravascular volume status, infection source control, antimicrobial adequacy, occult bleeding, pneumothorax, tamponade, pulmonary embolism, and septic cardiomyopathy rather than reflexive catecholamine escalation. [13][15]" ], "subsections": [], "table": { "caption": "Initial vasopressor decision points in adult septic shock. [5][10][20]", "columns": [ "Clinical finding", "Immediate action", "Interpretation that changes management" ], "rows": [ [ "MAP remains below 60-65 mm Hg after initial fluids or perfusion is deteriorating", "Begin norepinephrine and titrate to MAP at least 65 mm Hg. [5][11]", "Persistent vasodilation requires vasopressor support; do not defer therapy solely to finish fluid administration. [5]" ], [ "MAP reaches target but capillary refill, urine output, mentation, or lactate trajectory remains concerning", "Reassess cardiac output, volume responsiveness, source control, and competing shock states. [4][15]", "Pressure restoration alone does not establish adequate systemic or regional perfusion. [4]" ], [ "Norepinephrine dose is escalating", "Add fixed-dose vasopressin rather than relying exclusively on further norepinephrine escalation. [10][12]", "Use a noncatecholamine adjunct to reduce catecholamine exposure; approximately 0.25 µg/kg/min norepinephrine is a common practical threshold. [12]" ] ] } }, { "id": "choose-second-agent", "eyebrow": "Escalation", "heading": "How to select the second vasopressor", "intro": "Add a mechanistically complementary agent when norepinephrine requirements rise or MAP remains below target.", "paragraphs": [ "Add vasopressin to norepinephrine for persistent hypotension during dose escalation. The Surviving Sepsis Campaign suggests adding vasopressin rather than further escalating norepinephrine, and contemporary guidance describes a fixed infusion of 0.03 U/min, commonly considered when norepinephrine approaches 0.25 µg/kg/min. [10][12]", "Vasopressin is an adjunct, not routine first-line monotherapy. In VASST, low-dose vasopressin added to norepinephrine did not improve overall mortality or adverse events versus norepinephrine alone, although a less-severe sepsis subgroup had lower mortality. It can reduce norepinephrine requirements and may increase urine output, but neither response establishes renal recovery or adequate global perfusion. [8]", "Use epinephrine as an additional vasopressor when MAP remains inadequate despite norepinephrine, with or without vasopressin. It raises MAP but lacks demonstrated mortality benefit and may cause tachyarrhythmia and adrenergic hyperlactatemia; therefore, interpret a lactate increase after epinephrine initiation in the context of peripheral perfusion and other hemodynamic markers. [20][12]" ], "bullets": [ "Choose vasopressin preferentially when the immediate objective is norepinephrine-sparing vasoconstriction without adding beta-adrenergic stimulation. [10][12]", "Use epinephrine cautiously in atrial or ventricular tachyarrhythmias and when serial lactate is being used as the principal resuscitation signal. [10][20]", "Do not substitute dopamine for norepinephrine solely because inotropy is desired; dopamine increases tachyarrhythmia risk and is associated with worse outcomes than norepinephrine. [14][20]" ], "subsections": [ { "heading": "When a low-output phenotype changes selection", "paragraphs": [ "If bedside assessment suggests a low-output state—cool extremities, pulmonary congestion, new ventricular dysfunction, or poor perfusion despite a restored MAP—evaluate for septic cardiomyopathy or a concurrent cardiogenic process rather than treating all hypotension as vasoplegia. Mixed cardiogenic-vasodilatory shock generally still begins with norepinephrine because it provides vasoconstriction with modest inotropic activity and has fewer adverse events than high-dose dopamine or epinephrine. [2]", "Avoid angiotensin II in low-output syndrome because it can increase MAP while worsening afterload-dependent forward flow. In mixed shock, vasopressin may be preferable to angiotensin II when right-ventricular afterload is a concern. [2]" ], "bullets": [] } ], "table": { "caption": "Selection of adjunct vasopressors after norepinephrine in septic shock. [10][12][13][20]", "columns": [ "Agent", "Use case", "Important limitation or monitoring issue" ], "rows": [ [ "Vasopressin", "Add to escalating norepinephrine; fixed dose 0.03 U/min is recommended to reduce catecholamine exposure. [10][12]", "Not recommended as first-line replacement for norepinephrine; monitor for vasopressin-related ischemic or cardiac intolerance, especially when ventricular function is impaired. [10][12]" ], [ "Epinephrine", "Add when MAP remains inadequate despite norepinephrine, with or without vasopressin. [20]", "May increase lactate and provoke arrhythmias; do not equate isolated lactate rise with treatment failure. [20][12]" ], [ "Angiotensin II", "Consider only for refractory vasodilatory shock with high norepinephrine requirements after standard vasopressor escalation. In ATHOS-3, patients had norepinephrine requirements greater than 0.2 µg/kg/min for more than 6 hours. [13]", "Raises MAP in many patients but did not improve 28-day mortality in ATHOS-3; avoid in low-output syndrome and recognize potential right-ventricular afterload increase. [13][2]" ], [ "Dopamine", "Use only when norepinephrine is unavailable or a compelling patient-specific rationale outweighs risk. [10]", "Compared with norepinephrine, associated with higher mortality and more arrhythmia. [20][14]" ], [ "Phenylephrine", "Generally avoid for routine septic shock. [2]", "Can cause excessive vasoconstriction and tissue ischemia, has less hemodynamic efficacy, and may reduce cardiac output. [2][11]" ] ] } }, { "id": "refractory-vasodilatory-shock", "eyebrow": "Refractory shock", "heading": "When to consider angiotensin II and how to avoid harmful escalation", "intro": "Persistent hypotension despite multiple vasopressors requires phenotype reassessment before adding a third or fourth agent.", "paragraphs": [ "Consider angiotensin II only in refractory vasodilatory shock after norepinephrine-based therapy and usually after vasopressin. In ATHOS-3, angiotensin II increased MAP without increasing norepinephrine in 70% of patients with vasodilatory shock, most of whom had septic shock and were receiving norepinephrine greater than 0.2 µg/kg/min for more than 6 hours; the trial did not demonstrate a 28-day mortality benefit. [13]", "Do not use a fixed norepinephrine dose or elapsed shock duration as the sole determinant for vasopressin timing or further escalation. Vasopressor responsiveness must be interpreted with cardiac output, ventricular function, fluid tolerance, source control, and evidence of organ perfusion. [13][2]", "An unexpectedly poor pressor response should prompt a focused search for a nonvasoplegic component. Obtain bedside echocardiography when low-output or right-ventricular failure is plausible, and urgently identify reversible obstructive or hemorrhagic causes. In a low-output syndrome, angiotensin II is contraindicated; continued pure afterload augmentation can impair forward flow even if MAP rises. [2][15]" ], "bullets": [ "Avoid phenylephrine as a routine rescue vasopressor because excessive vasoconstriction, tissue ischemia, and reduced cardiac output are concerns. [2][11]", "In severe mitral stenosis with cardiogenic shock, tachycardia may worsen hemodynamics; phenylephrine with or without vasopressin can be reasonable in that specific valvular phenotype rather than a general sepsis strategy. [17]", "In acute severe aortic regurgitation with hypotension, pure vasoconstrictors can worsen regurgitation; norepinephrine or epinephrine may be better tolerated when vasoconstriction and inotropy are needed. [17]" ], "subsections": [], "table": { "caption": "Findings that should redirect vasopressor escalation toward hemodynamic phenotyping. [2][4][15][17]", "columns": [ "Finding during escalation", "Likely concern", "Next action" ], "rows": [ [ "MAP improves but peripheral perfusion or lactate trajectory does not", "Inadequate flow, persistent regional hypoperfusion, uncontrolled infection, or nonhypoperfusion lactate generation. [4]", "Integrate examination, urine output, serial lactate, and cardiac output assessment; reassess source control and vasoactive effects. [4]" ], [ "Cool shock, pulmonary congestion, or suspected ventricular dysfunction", "Mixed cardiogenic-vasodilatory shock or septic cardiomyopathy. [2]", "Perform bedside cardiac assessment; retain norepinephrine as the usual initial vasopressor but avoid angiotensin II in low-output syndrome. [2]" ], [ "Escalating vasoactive support without a durable MAP response", "Uncorrected cause of refractory shock. [15]", "Reassess volume status, hemorrhage, tamponade, pneumothorax, pulmonary embolism, antimicrobial therapy, and source control. [15][13]" ], [ "New tachyarrhythmia or disproportionate lactate rise after epinephrine", "Adrenergic adverse effect or drug-associated lactate generation. [20][12]", "Assess perfusion by multiple endpoints before escalating for lactate alone; reconsider catecholamine burden. [4][20]" ] ] } }, { "id": "monitor-response-and-harm", "eyebrow": "Monitoring", "heading": "How to judge response and detect vasopressor-related harm", "intro": "Use a multimodal perfusion assessment and titrate to the lowest effective catecholamine burden.", "paragraphs": [ "Monitor response at the bedside with MAP, serial vasopressor dose, capillary refill and extremity perfusion, urine output, mentation, and lactate trend. Lactate is prognostically useful but biologically nonspecific in shock: reduced cardiac output and global hypoperfusion cause type A elevation, whereas endogenous or exogenous adrenergic stimulation can produce type B elevation. [4]", "Avoid interpreting an epinephrine-associated lactate increase as automatic evidence of worsening shock. A discordant pattern—improving capillary refill, MAP, urine output, and clinical perfusion with rising lactate after epinephrine—should lead to reassessment of adrenergic lactate generation rather than uncritical escalation of vasopressors. [4][20]", "Actively surveil for tachyarrhythmia with catecholamines, especially dopamine and epinephrine. The norepinephrine-versus-dopamine evidence base shows lower mortality with norepinephrine (risk ratio 0.89, 95% CI 0.81-0.98) and fewer arrhythmias (risk ratio 0.48, 95% CI 0.40-0.58). [20]", "Once MAP and perfusion stabilize, down-titrate vasopressors while continuing to reassess the underlying shock driver. A decline in dose requirement is favorable only when accompanied by sustained pressure and perfusion; do not accept a lower dose at the cost of recurrent hypotension or deteriorating end-organ function. [5][15]" ], "bullets": [ "Document the vasopressor dose trajectory with the clinical perfusion assessment; dose escalation alone is neither a diagnostic category nor a measure of resuscitation success. [4][13]", "If peripheral ischemia develops, reassess the balance between required perfusion pressure, shock severity, and excessive vasoconstrictor exposure; phenylephrine is particularly associated with peripheral, renal, mesenteric, and myocardial ischemia concerns. [11][2]", "Treat the infection and obtain source control in parallel with hemodynamic support; no vasoactive regimen corrects ongoing uncontrolled sepsis. [13]" ], "subsections": [], "table": { "caption": "Monitoring endpoints during vasopressor therapy for septic shock. [4][5][20]", "columns": [ "Endpoint", "Actionable interpretation", "Response" ], "rows": [ [ "MAP", "Initial goal is at least 65 mm Hg. [5]", "Titrate norepinephrine first; add vasopressin during escalation rather than pursuing catecholamine-only escalation. [10][12]" ], [ "Lactate trend", "May reflect hypoperfusion, adrenergic stimulation, or other nonhypoperfusion mechanisms. [4]", "Interpret with clinical perfusion and drug exposure, particularly after epinephrine initiation. [4][20]" ], [ "Rhythm", "New tachyarrhythmia may be catecholamine-related; dopamine has a higher arrhythmia burden than norepinephrine. [20]", "Reduce avoidable catecholamine exposure and favor norepinephrine-based therapy with vasopressin adjunct when appropriate. [10][20]" ], [ "Peripheral perfusion", "Worsening coolness, ischemic changes, or delayed capillary refill may reflect ongoing shock or excessive vasoconstriction. [4][11]", "Reassess shock phenotype, dose burden, and the need for agents prone to excessive vasoconstriction such as phenylephrine. [2][11]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Optimal Perfusion Targets in Cardiogenic Shock", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2022.100034", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 2, "title": "Mixed Cardiogenic-Vasodilatory Shock: Current Insights and Future Directions", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2024.101432", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 3, "title": "Norepinephrine as a First-Line Inopressor in Cardiogenic ...", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2018.04.052", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 4, "title": "Macrovascular Hemodynamics and Peripheral Perfusion in Cardiogenic Shock: Exploring Current Targets and Future Directions", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.101964", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 5, "title": "Current use of vasopressors in septic shock", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2110582025009203", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 6, "title": "Review article Hemodynamic failure during sepsis: What clinicians ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2352556825001341", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 7, "title": "Severe Sepsis and Septic Shock: Clinical Overview and Update on ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0025619614006636", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Vasopressin Blood Level - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/vasopressin-blood-level", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "Optimizing Timing and Dose of Starting Norepinephrine and Vasopressin in Septic Shock", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13302258", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 10, "title": "Surviving sepsis campaign: international guidelines for ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8486643", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 11, "title": "Inotropes and Vasopressors - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK482411", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 12, "title": "Current and future strategies aiming at reducing catecholamine exposure in septic shock", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13483425", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 13, "title": "Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12306101", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 14, "title": "Early Recognition and Initial Management of Sepsis in Adult Patients", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK598311", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 15, "title": "Refractory Shock - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK564427", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 16, "title": "Lactate metabolism in human health and disease", "detail": "uat.ajnr.org", "url": "https://uat.ajnr.org/lookup/external-ref?access_num=10.1038%2Fs41392-022-01151-3&link_type=DOI", "authors": "uat.ajnr.org", "host": "uat.ajnr.org" }, { "number": 17, "title": "Acute Decompensated Valvular Disease in the Intensive Care Unit", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2024.101402", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 18, "title": "Early vasopressin plus norepinephrine versus delayed or no vasopressin in septic shock: A systematic review and meta-analysis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0735675725006643", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "How We Escalate Vasopressor and Corticosteroid Therapy in Patients With Septic Shock - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0012369222038879", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 20, "title": "The Surviving Sepsis Campaign: Fluid Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7963440", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Resuscitation Targets, Fluids, and Vasoactives in Septic Shock", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12917878", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Vasopressors in septic shock: which, when, and how much?", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7333107", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 23, "title": "It’s Time to Consider How We Should Use Vasopressors, Rather Than Just Which We Should Use", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12422763", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public Databases", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12377302", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Optimal Perfusion Targets in Cardiogenic Shock", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2022.100034", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "of both agents among 57 patients with AMI-CS and found that patients treated with epinephrine had higher rates of refractory shock and lactic acidosis.3 While the trial is limited by a small sample size and short follow-up duration in an isolated AMI-CS cohort, these findings have tempered the use o", "score": 0.69573146 }, { "number": 2, "title": "Mixed Cardiogenic-Vasodilatory Shock: Current Insights and Future Directions", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2024.101432", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "Download figure\n Download PowerPoint\n\nSocietal guidelines recommend norepinephrine as the first-choice vasopressor for both cardiogenic and septic shock, making norepinephrine an appropriate first-line vasopressor for most patients with mixed shock.2,46,67 Norepinephrine largely acts as a peripher", "score": 0.6899958 }, { "number": 3, "title": "Norepinephrine as a First-Line Inopressor in Cardiogenic ...", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2018.04.052", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "by S van Diepen · 2018 · Cited by 28 — The selection of norepinephrine as an active comparator is appropriate and likely stems from the SOAP (Sepsis Occurrence in Acutely Ill Patients) II trial, ...Read more", "score": 0.35019964 }, { "number": 4, "title": "Macrovascular Hemodynamics and Peripheral Perfusion in Cardiogenic Shock: Exploring Current Targets and Future Directions", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.101964", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "during shock or exogenous administration as vasopressor agents) or mitochondrial dysfunction, particularly with concomitant sepsis.48 Thus, while lactate elevation is often assumed to reflect inadequate perfusion in CS, it is critical to consider other potential contributing mechanisms, particularly", "score": 0.19155477 }, { "number": 5, "title": "Current use of vasopressors in septic shock", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2110582025009203", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Results\n\nA total of 839 physicians from 82 countries (65% main specialty/activity intensive care) responded. The main trigger for vasopressor use was an insufficient mean arterial pressure (MAP) response to initial fluid resuscitation (83%). The first-line vasopressor was norepinephrine (97%), t", "score": 0.7004242 }, { "number": 6, "title": "Review article Hemodynamic failure during sepsis: What clinicians ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2352556825001341", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "The most recent edition of the SSC strongly recommends initiation of norepinephrine as a first-line vasopressor after adequate resuscitation [3].", "score": 0.62248284 }, { "number": 7, "title": "Severe Sepsis and Septic Shock: Clinical Overview and Update on ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0025619614006636", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Norepinephrine is recommended as the first choice for vasopressor use in patients with septic shock. Dopamine had been used widely as a first-", "score": 0.60386235 }, { "number": 8, "title": "Vasopressin Blood Level - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/vasopressin-blood-level", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Even though it is not considered a first-line therapy, vasopressin is used as an adjunct to catecholamines in the treatment of septic shock. Patients with septic shock have much lower plasma vasopressin concentrations than those with cardiogenic shock. This has been interpreted as a relative vasopre", "score": 0.54840803 }, { "number": 9, "title": "Optimizing Timing and Dose of Starting Norepinephrine and Vasopressin in Septic Shock", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13302258", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "This review summarizes the current evidence regarding the pharmacological rationale, timing, and dosing of NE in septic shock and discusses the physiological and clinical considerations for adjunctive AVP therapy. A practical strategy is proposed, emphasizing early and sufficiently dosed NE followed", "score": 0.8170061 }, { "number": 10, "title": "Surviving sepsis campaign: international guidelines for ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8486643", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Thus, we considered the desirable and undesirable consequences of these vasopressors and issued a strong recommendation to use norepinephrine as a first line agent instead of dopamine, vasopressin, epinephrine and selepressin and angiotensin II in patients with septic shock as a first-line agent, an", "score": 0.8091708 }, { "number": 11, "title": "Inotropes and Vasopressors - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK482411", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "The American College of Critical Care Medicine (ACCM) guidelines recognize that a MAP of 60 to 65 mm Hg is required to perfuse organs. Vasopressors should be initiated if the MAP does not improve to about 60 mm Hg after appropriate fluid resuscitation. Norepinephrine is recommended as the initial va", "score": 0.7500592 }, { "number": 12, "title": "Current and future strategies aiming at reducing catecholamine exposure in septic shock", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13483425", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Recent Surviving Sepsis Campaign guidelines recommend adding vasopressin (fixed dose 0.03 U/min) to reduce catecholamine exposure, typically when norepinephrine requirements reach approximately 0.25 µg/kg/min . However, previous RCTs have not consistently excluded patients at risk of vasopressin-rel", "score": 0.74807674 }, { "number": 13, "title": "Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12306101", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "According to the Surviving Sepsis Campaign (SSC), the treatment of septic shock is based on controlling the source of infection, antimicrobial therapy and hemodynamic management combining the administration of fluids and vasopressors, with norepinephrine being the recommended first-line vasopressor ", "score": 0.7458619 }, { "number": 14, "title": "Early Recognition and Initial Management of Sepsis in Adult Patients", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK598311", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Studies have evaluated additional agents including vasopressin, epinephrine, and phenylephrine in comparison to norepinephrine as a first-line vasopressor in septic shock. There was no significant difference between vasopressin and norepinephrine82,83 in terms of 28-day mortality, and when vasopress", "score": 0.5775198 }, { "number": 15, "title": "Refractory Shock - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK564427", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Crit Care Med. 2013 Feb; 41(2):580-637.\n Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.[Crit Care Med. 2008]\n\n Survivin", "score": 0.5313802 }, { "number": 16, "title": "Lactate metabolism in human health and disease", "detail": "uat.ajnr.org", "url": "https://uat.ajnr.org/lookup/external-ref?access_num=10.1038%2Fs41392-022-01151-3&link_type=DOI", "authors": "uat.ajnr.org", "host": "uat.ajnr.org", "snippet": "by X Li · 2022 · Cited by 1795 — Lactate clearance and vasopressor seem to be predictors for mortality in severe sepsis patients with lactic acidosis supplementing sodium", "score": 0.43108177 }, { "number": 17, "title": "Acute Decompensated Valvular Disease in the Intensive Care Unit", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2024.101402", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "Given the unique pathophysiology, cardiogenic shock complicated by MS can be particularly challenging to manage. Vasopressor selection should include consideration of the potential impact on heart rate. Norepinephrine is often the first line for cardiogenic shock, and while not an unreasonable selec", "score": 0.13045175 }, { "number": 18, "title": "Early vasopressin plus norepinephrine versus delayed or no vasopressin in septic shock: A systematic review and meta-analysis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0735675725006643", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## Declaration of competing interest\n\n## References (28)\n\n### 14 - Autonomic nervous system pharmacology\n\n### Refractory septic shock and alternative wordings: a systematic review of literature\n\n### J Crit Care\n\n### Hemodynamic effects of adjunct arginine vasopressin to norepinephrine in septic shoc", "score": 0.54594 }, { "number": 19, "title": "How We Escalate Vasopressor and Corticosteroid Therapy in Patients With Septic Shock - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0012369222038879", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Intensive Care Med\n\n### Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial\n\n### JAMA\n\n### Angiotensin II for the treatment of vasodilatory shock\n\n### N Engl J Med\n\n### Hydrocortisone plus fludrocortisone for adults ", "score": 0.4169159 }, { "number": 20, "title": "The Surviving Sepsis Campaign: Fluid Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7963440", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Norepinephrine is recommended as a first-line vasopressor agent for the treatment of septic shock (62). A systematic review and meta-analysis of 11 randomized trials reported that norepinephrine use resulted in lower mortality (RR, 0.89; 95% CI, 0.81–0.98) and decreased risk of arrhythmias (RR, 0.48", "score": 0.72907686 }, { "number": 21, "title": "Resuscitation Targets, Fluids, and Vasoactives in Septic Shock", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12917878", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "92.. Landry, Levin, Gallant, _et al._ Vasopressin deficiency contributes to the vasodilation of septic shock. _Circulation_ 1997;95:1122–5. doi: 10.1161/01.cir.95.5.1122 [DOI] [PubMed] [Google Scholar]\n 93.. Russell, Walley, Singer, _et al._ Vasopressin versus norepinephrine infusion in patients ", "score": 0.644248 }, { "number": 22, "title": "Vasopressors in septic shock: which, when, and how much?", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7333107", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "In spite of recently published expert consensus statements on the use of vasopressors in septic shock (3), controversies still exist on some issues (4) such as, whether very early use of norepinephrine (NE) could improve outcome, whether individualized target of mean arterial pressure (MAP) should b", "score": 0.60386235 }, { "number": 23, "title": "It’s Time to Consider How We Should Use Vasopressors, Rather Than Just Which We Should Use", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12422763", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "13.. Bauer, Wieruszewski, Bissell Turpin, _et al._: Adjunctive vasopressors and short-term mortality in adults with septic shock: A systematic review and meta-analysis. _Shock_ 2025; 63:668–676 doi: 10.1097/SHK.0000000000002558 [DOI] [PMC free article] [PubMed] [Google Scholar]\n 14.. White, Costa", "score": 0.58777803 }, { "number": 24, "title": "Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public Databases", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12377302", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "40..U.S. National Institutes of Health: Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock (EVSS). ClinicalTrials.gov. Available at: Accessed May 1, 2025 [Google Scholar]\n 41..U.S. National Institutes of Health: Vasopressin for Septic Shock Pragmatic Trial (VASSPR). C", "score": 0.5660431 } ], "publishedAt": "2026-09-15T21:58:43.570520+00:00", "updatedAt": "2026-09-15T21:58:43.570520+00:00", "readingMinutes": 5, "slug": "sepsis-vasopressor-selection" }